share_log

12 Health Care Stocks Moving In Wednesday's After-Market Session

Benzinga ·  Mar 28 04:31

Gainers

  • Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The market value of their outstanding shares is at $12.0 million.
  • Fresh2 Group (NASDAQ:FRES) stock moved upwards by 5.26% to $0.6. The company's market cap stands at $14.2 million.
  • Biora Therapeutics (NASDAQ:BIOR) shares rose 5.12% to $1.23. The company's market cap stands at $33.4 million. As per the news, the Q4 earnings report came out yesterday.
  • Athira Pharma (NASDAQ:ATHA) stock rose 5.07% to $2.69. The market value of their outstanding shares is at $103.0 million.
  • Clearside Biomedical (NASDAQ:CLSD) stock rose 4.79% to $1.75. The company's market cap stands at $130.7 million.
  • TFF Pharmaceuticals (NASDAQ:TFFP) stock increased by 4.7% to $6.9. The market value of their outstanding shares is at $16.3 million.

Losers

  • Strata Skin Sciences (NASDAQ:SSKN) stock fell 12.5% to $0.39 during Wednesday's after-market session. The market value of their outstanding shares is at $13.6 million. As per the press release, Q4 earnings came out today.
  • Yield10 Bioscience (NASDAQ:YTEN) stock declined by 9.36% to $0.34. The company's market cap stands at $4.0 million.
  • Modular Medical (NASDAQ:MODD) stock declined by 9.24% to $1.77. The company's market cap stands at $54.8 million.
  • GlycoMimetics (NASDAQ:GLYC) stock fell 8.81% to $2.9. The company's market cap stands at $186.7 million. As per the news, the Q4 earnings report came out today.
  • Titan Pharma (NASDAQ:TTNP) shares fell 5.15% to $7.0. The market value of their outstanding shares is at $5.2 million.
  • Alzamend Neuro (NASDAQ:ALZN) stock declined by 5.01% to $0.99. The company's market cap stands at $6.5 million. The company's, Q3 earnings came out 2 days ago.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment